Losartan for Renoprotection in Chronic Kidney Disease

Efficacy of Losartan in CKD

Losartan provides significant renoprotection in patients with chronic kidney disease, reducing proteinuria by approximately 20–47 % and slowing the decline in glomerular filtration rate independent of blood‑pressure lowering effects【1】.

For adults with CKD stage 3–4 and proteinuria, start losartan at 50 mg once daily【1】.
After 2–4 weeks, titrate the dose to 100 mg once daily to achieve the maximal renoprotective benefit demonstrated in clinical trials【1】.
Underdosing (≤50 mg daily) fails to deliver the proven renoprotective effect and should be avoided【1】.

Check serum creatinine (or eGFR) and serum potassium within 2–4 weeks after starting losartan or after any dose increase【1】.
An increase in serum creatinine of up to 30 % within the first 4 weeks is expected and does not require discontinuation; therapy should be continued unless the rise exceeds 30 %【1】.
Ongoing monitoring of urinary albumin excretion is recommended to evaluate treatment response and disease progression【2】.

Losartan may raise serum potassium by roughly 1 mEq/L; hyperkalemia should first be addressed with dietary potassium restriction, cessation of potassium‑containing supplements, and potassium‑binding agents rather than dose reduction or drug discontinuation【1】.

Losartan should be maintained even when eGFR falls below 30 mL/min/1.73 m², provided there is no symptomatic hypotension or uncontrolled hyperkalemia【1】.
Continuation is also reasonable when eGFR declines below 20 mL/min/1.73 m², unless the drug is poorly tolerated or the patient initiates renal replacement therapy【1】.
Dose reduction or discontinuation is reserved for symptomatic hypotension, refractory hyperkalemia, or severe uremic symptoms when eGFR is < 15 mL/min/1.73 m²【1】.

Dual blockade of the renin‑angiotensin‑aldosterone system (combining losartan with an ACE inhibitor or aliskiren) markedly increases the risk of hyperkalemia, syncope, and acute kidney injury (2–3‑fold) without added cardiovascular benefit; the ACC/AHA guidelines assign a Class III: Harm recommendation to this combination【3】【1】.

Do not discontinue losartan for mild, transient creatinine rises (< 30 %); this reflects hemodynamic changes rather than renal injury【1】.
Do not stop losartan solely for modest hyperkalemia; first employ potassium‑lowering strategies before altering the regimen【1】.
Do not withhold losartan in advanced CKD solely because of low eGFR; continuation confers cardiovascular and renal benefits when tolerated【1】.

The American College of Cardiology recommends starting losartan at 50 mg once daily and titrating to 100 mg once daily to achieve maximum renoprotective benefits, as clinical trials demonstrating kidney protection used these higher doses 4, 5
For patients with moderately to severely increased albuminuria (A2-A3) with diabetes, start at 50 mg and increase to 100 mg once daily 4, 5
The European Society of Cardiology recommends a target dose of 100 mg once daily for maximum renoprotection 4, 5

Monitor serum creatinine, serum potassium, and blood pressure within 2-4 weeks of initiation or dose increase, and accept up to 30% increase in serum creatinine within 4 weeks 5
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring for hyperkalemia and managing with potassium-lowering measures rather than stopping losartan when possible 5
Assess for symptomatic hypotension and adjust the dose accordingly 5

Continue losartan even when eGFR falls below 30 mL/min/1.73 m², unless symptomatic hypotension or uncontrolled hyperkalemia develops 5
The European Heart Journal recommends targeting office BP 130-139/80-90 mmHg for most CKD patients, and considering targeting systolic BP 120-129 mmHg if tolerated for eGFR >30 mL/min/1.73 m² 5, 6
RAS blockers like losartan are recommended as part of the treatment strategy for hypertensive CKD patients with albuminuria 6

Don't stop losartan for mild creatinine increases (<30%): this is expected and does not indicate harm 5
Don't underdose: the proven renoprotective benefits in trials were achieved with 100 mg daily, not lower doses 4, 5
Don't discontinue prematurely for hyperkalemia: manage potassium medically before reducing or stopping losartan 5